the Company’s board of directors (the “Board”) appointed Andrew Gengos as the Company’s Chief Financial Officer and Chief Business Officer, effective May 18, 2023.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Glenna Mileson resigned as Chief Financial Officer at LeonaBio, Inc..
Action
resigned
Role
Chief Financial Officer
Exact text from the filing
Glenna Mileson, the Company’s Chief Financial Officer, resigned from her position as Chief Financial Officer on May 18, 2023 effective immediately.
Andrew Gengos was appointed as Chief Financial Officer and Chief Business Officer at LeonaBio, Inc..
Action
appointed
Role
Chief Financial Officer and Chief Business Officer
Exact text from the filing
the Company’s board of directors (the “Board”) appointed Andrew Gengos as the Company’s Chief Financial Officer and Chief Business Officer, effective May 18, 2023.
LeonaBio, Inc. shareholders approved Election of Class III Directors at the 2023-05-18 meeting.
Proposal
director election
Outcome
passed
Meeting
2023-05-18
Exact text from the filing
Proposal No. 1 – Election of Class III Directors The stockholders elected the two candidates nominated by the Company’s Board of Directors (the “Board”) to serve as directors of the Company until the annual meeting of stockholders to be held in 2026 or until their successors are elected and qualified. The following sets forth the results of the voting with respect to each candidate: Nominees of the Board For Withhold Broker Non-Votes Kelly A. Romano 13,993,414 3,466,402 9,303,812 James A. Johnson 14,519,313 2,940,503 9,303,812
LeonaBio, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-18 meeting.
Proposal
auditor ratification
Outcome
passed
Meeting
2023-05-18
Exact text from the filing
Proposal No. 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023. The following sets forth the results of the voting with respect to this proposal: For Against Abstain Broker Non-Votes 26,704,561 39,131 19,936 0
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.